Relay Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Relay Therapeutics, Inc. (RLAY) reported Revenue from Contract with Customer, Excluding Assessed Tax of $350.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Relay Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $350.00K, a 48.30% decline year-over-year.
- Relay Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $3.00M, a 60.93% decline year-over-year.
- Relay Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $7.00M.
- Relay Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00.
- Relay Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $15.36M, a 53.44% increase from fiscal 2024.
- Relay Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $10.01M, a 60.83% decline from fiscal 2023.
- Relay Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $25.55M, a 1749.82% increase from fiscal 2022.
- Relay Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.38M, a 54.41% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $350.00K 10-Q · filed 2026-08-06 | $3.35M 10-Q · filed 2026-08-06 | $10.35M derived: sum of 3 quarters · filed 2026-08-06 | $10.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.00M 10-Q · filed 2026-05-05 | $10.00M derived: sum of 2 quarters · filed 2026-05-05 | $10.00M derived: sum of 3 quarters · filed 2026-05-05 | $10.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.00M derived: sum of 2 quarters · filed 2026-02-26 | $7.68M derived: sum of 3 quarters · filed 2026-08-06 | $15.36M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $677.00K derived: sum of 2 quarters · filed 2026-08-06 | $8.36M 10-Q · filed 2025-11-06 | $8.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $677.00K 10-Q · filed 2026-08-06 | $8.36M 10-Q · filed 2026-08-06 | $8.36M derived: sum of 3 quarters · filed 2026-08-06 | $8.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.68M 10-Q · filed 2026-05-05 | $7.68M derived: sum of 2 quarters · filed 2026-05-05 | $7.68M derived: sum of 3 quarters · filed 2026-05-05 | $7.68M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $10.01M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $10.01M 10-Q · filed 2025-11-06 | $10.01M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $10.01M 10-Q · filed 2025-08-07 | $10.01M derived: sum of 3 quarters · filed 2026-02-26 | $35.21M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $10.01M 10-Q · filed 2025-05-05 | $10.01M derived: sum of 2 quarters · filed 2026-02-26 | $35.21M derived: sum of 3 quarters · filed 2026-02-26 | $35.33M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.20M derived: sum of 2 quarters · filed 2026-02-26 | $25.32M derived: sum of 3 quarters · filed 2026-02-26 | $25.55M 10-K · filed 2026-02-26 |
| 2023-09-30 | $25.20M 10-Q · filed 2024-11-06 | $25.32M derived: sum of 2 quarters · filed 2024-11-06 | $25.55M 10-Q · filed 2024-11-06 | $25.80M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $119.00K 10-Q · filed 2024-08-06 | $345.00K 10-Q · filed 2024-08-06 | $598.00K derived: sum of 3 quarters · filed 2025-02-26 | $942.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $226.00K 10-Q · filed 2024-05-02 | $479.00K derived: sum of 2 quarters · filed 2025-02-26 | $823.00K derived: sum of 3 quarters · filed 2025-02-26 | $1.19M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $253.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $597.00K derived: sum of 2 quarters · filed 2025-02-26 | $962.00K derived: sum of 3 quarters · filed 2025-02-26 | $1.38M 10-K · filed 2025-02-26 |
| 2022-09-30 | $344.00K 10-Q · filed 2023-11-02 | $709.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.13M 10-Q · filed 2023-11-02 | $1.70M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $365.00K 10-Q · filed 2023-08-08 | $784.00K 10-Q · filed 2023-08-08 | $1.35M derived: sum of 3 quarters · filed 2024-02-22 | $2.02M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $419.00K 10-Q · filed 2023-05-04 | $986.00K derived: sum of 2 quarters · filed 2024-02-22 | $1.65M derived: sum of 3 quarters · filed 2024-02-22 | $2.50M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $567.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.23M derived: sum of 2 quarters · filed 2024-02-22 | $2.08M derived: sum of 3 quarters · filed 2024-02-22 | $3.03M 10-K · filed 2024-02-22 |
| 2021-09-30 | $666.00K 10-Q · filed 2022-11-03 | $1.51M derived: sum of 2 quarters · filed 2022-11-03 | $2.46M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $844.00K 10-Q · filed 2022-08-04 | $1.80M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $952.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $82.65M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |